Association between restriction fragment length polymorphism of the L‐<i>myc</i> gene and lung metastasis in human breast cancer

Mh, Champème; Bièche, Ivan; Latil, Alain; Hacène, K.; Lidereau, Rosette

doi:10.1002/ijc.2910500103

Cited by 18 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results confirm those of Ikeda et al in colorectal cancer (1988), Tefre et al in lung cancer in Norway (1990), Ishizaki et al (1990) and Champeme et al (1992) in breast cancer, Saranath et al (1990) in oral cancer, Weston et al (1992) in lung cancer in the USA, Mironov et al (1994) in gastric cancer in Russia and Presti et al (1996) in renal cancer. On the other hand L-myc RFLP is correlated with the extent of metastasis of lung cancer in Japan (Kawashima et al, 1988(Kawashima et al, , 1992 and in renal cancer (Kakehi and Yoshida, 1989); Ishizaki et al (1990) also reported that the presence of the S-allele is associated with poor prognosis due to metastasic lesion in gastric cancer.…”

Section: Discussionsupporting

confidence: 91%

“…The role of L-myc in cancer susceptibility has been implied by studies showing differences in genotype frequencies between cancer patients and controls Dolcetti et al, 1991;Crossen et al, 1994). The role of L-myc in prognosis has been suggested by studies showing that, among cancer patients, those that carry an Sallele (either LS or SS genotype) have earlier lymph node involvement or metastasis, or poorer survival than those who have genotype LL (Kakehi and Yoshida, 1989;Champeme et al, 1992;Kawashima et al, 1992). In contrast, Taylor et al (1993) reported a protective effect for the SS genotype in hepatocellular carcinoma.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Restriction fragment length polymorphism of the L-myc gene is not a prognostic factor in bladder cancer patients

et al. 1999

View full text Add to dashboard Cite

The restriction enzyme Eco RI identifies a two-allele system for the L-myc gene with fragment sizes of 10.0 and 6.6 kilobases and results in three possible allelotypes: homozygotic for the large allele (LL), homozygotic for the small allele (SS) or heterozygotic (LS). The prognostic significance of the L-myc allelotype of genomic DNA has been studied previously in several tumours (lung, colorectal, breast, soft tissue, leukaemia, lymphoma, stomach, kidney, oral cavity and liver). However, conficting results were reported. In this study we have investigated the L-myc genotype of 98 primary bladder cancer patients in an attempt to determine its utility as a prognostic, and as a susceptibility, factor in a Catalonian population. MATERIALS AND METHODSNinety-eight patients (88 males, 10 females, aged 38-91), diagnosed at Fundació Puigvert as having primary bladder cancer, were studied for L-myc restriction fragment length polymorphism (RFL); P 53 were superficial bladder tumours and 45 were invasive tumours. In addition, 110 normal DNA specimens from healthy blood donors (66 males, 44 females, aged 2-81) were analysed to investigate the genotype frequency of L-myc proto-oncogene.High molecular weight DNA was isolated by standard phenol-chloroform methods. Restriction digests of DNA were performed with endonuclease Eco RI under standard conditions, electrophoresed in a 0.8% agarose gel, denaturated, transferred to Hybond® nylon membrane (Amersham) and hybridized with a 32 P-labelled probe by the method essentially described by Southern (1975).All results obtained in these studies were analysed for statistical significance by the χ 2 test with Yates' correction for adjustment when necessary. Differences between the two populations were judged significant at P < 0.05. Kaplan-Meier curves were constructed to analyse patient survival between different genotypes (log-rank test). RESULTSEco RI-digested DNA probed with the L-myc probe results in two fragments of 10 kb (L) and 6.6 kb (S), which are due to an Eco RI restriction site polymorphism (Figure 1). The distribution of the three genotypes (LL, LS, SS) in the control and patient groups is shown in Table 1. Chi-squared analysis showed that there was no difference between the distribution of the three genotypes of patient group and controls, and all are in accordance with Hardy-Weinberg equilibrium.When the patients in the current study were examined for a relationship between the presence of S-alleles (LS or SS individuals) and distant metastasis, no association was found (P = 0.51). Nor was there a significant association between homozygosity for the Summary The L-myc restriction fragment length polymorphism has been suggested to be of prognostic significance in some types of primary tumours. We examined the prognostic and susceptibility significance of the L-myc genotype in a group of 98 bladder cancer patients. The L-myc genotype did not correlate with any pathologic parameter and does not offer any clinical utility in patients with bladder cancer.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Restriction fragment length polymorphism of the L-myc gene is not a prognostic factor in bladder cancer patients

et al. 1999

View full text Add to dashboard Cite

show abstract

“…RR, relative risk; 95%CI, 95% confidence interval. myc in prognosis, studies on lung, 4) kidney, 2) stomach, 5) bone or soft tissue sarcomas, 8) and breast 9) showed that the presence of the S-allele (either LS or SS genotype) was associated with earlier lymph node involvement or metastasis, or a poorer prognosis than that of the LL genotype. However, a clear correlation between the L-myc RFLP and susceptibility to cancer or prognosis was found only in certain types of cancers or restricted populations.…”

Section: Discussionmentioning

confidence: 99%

L‐myc Restriction Fragment Length Polymorphism in Japanese Patients with Esophageal Cancer

Shibuta

Inoue

Sato

et al. 2000

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

L-myc polymorphism is a representative genetic trait related to an individual's susceptibility to several cancers. However, there have been no reports concerning the association between esophageal cancer and L-myc polymorphism. To analyze the distribution of polymorphism in Japanese patients with esophageal cancer, a molecular genotyping method using a polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) was used. Based on an analysis of 65 Japanese patients with esophageal cancer and 107 healthy control subjects, a significant difference was observed in either the distribution of genotypes (P = = = =0.012) or of allele frequencies between the two groups (P = = = =0.004). The relative risk of esophageal cancer for genotypes including the shorter allele was 2.9 compared to the longer allele homozygote. Furthermore, the patients with S-allele had a tendency for poor prognosis among those with three genotypes. A significant difference between the distribution of genotypes and the incidence of lymph node metastasis was found based on the clinicopathological features of the cancers. These results suggest that L-myc polymorphism may be implicated as a genetic trait affecting an individual's susceptibility to esophageal cancer, at least among Japanese patients.

show abstract

“…Scattered reports have suggested that individuals bearing the`short' (S) allele either have an increased incidence of certain tumors and/or that such tumors manifest a more aggressive behavior. The associated neoplasms include soft-tissue sarcomas (Kato et al, 1990), oral cancers (Saranath et al, 1990), colorectal cancers (Young et al, 1994), nonHodgkin's lymphoma (Crossen et al, 1994), breast cancer (Champeme et al, 1992), and non-SCLC lung cancer (Kawashima et al, 1988). In contrast, at least one report has suggested that the`SS' genotype protects against hepatocellular cancer (Taylor et al, 1993).…”

Section: Small Cell Lung Cancer (Sclc)mentioning

confidence: 99%

MYC oncogenes and human neoplastic disease

1999

View full text Add to dashboard Cite

c-myc, N-myc and L-myc are the three members of the myc oncoprotein family whose role in the pathogenesis of many human neoplastic diseases has received wide empirical support. In this review, we ®rst summarize data, derived mainly from non-clinical studies, indicating that these oncoproteins actually serve quite di erent roles in vivo. This concept necessarily lies at the heart of the basis for the observation that the deregulated expression of each MYC gene is reproducibly associated with only certain naturally occurring malignancies in humans and that these genes are not interchangeable with respect to their aberrant functional consequences. We also review evidence implicating each of the above MYC genes in speci®c neoplastic diseases and have attempted to identify unresolved questions which deserve further basic or clinical investigation. We have made every attempt to review those diseases for which signi®cant and con®rmatory evidence, based on studies with primary tumor material, exists to implicate MYC members in their causation and/or progression.

show abstract

Association between restriction fragment length polymorphism of the L‐myc gene and lung metastasis in human breast cancer

Cited by 18 publications

References 27 publications

Restriction fragment length polymorphism of the L-myc gene is not a prognostic factor in bladder cancer patients

Restriction fragment length polymorphism of the L-myc gene is not a prognostic factor in bladder cancer patients

L‐myc Restriction Fragment Length Polymorphism in Japanese Patients with Esophageal Cancer

MYC oncogenes and human neoplastic disease

Contact Info

Product

Resources

About